Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 33

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 33
---
 Rights as Shareholder Until Exercise. Except as set forth in the warrants, the holders of the warrants do not have any voting rights,
dividends or other rights as a holder of our capital stock until they exercise the warrants.

Series G Warrants, Series H Warrants and Warrant Agent Warrants

The
following is a brief summary of the Series G Warrants, Series H Warrants, and Warrant Agent Warrants, issued in connection with the Closing
and is subject in all respects to the provisions contained in the applicable warrants, which are filed as exhibits to our Report on Form
6-K dated May 22, 2024. Unless otherwise stated, references to warrants in this subsection include the Series G Warrants, Series H Warrants
and Warrant Agent Warrants.

Exercisability.
The warrants became exercisable on May 24, 2024. The Series G Warrants, Series H Warrants and Warrant Agent Warrants expire five years,
five years and three years, respectively from the initial exercise date. The holder shall deliver the aggregate exercise price for the
Depositary Shares specified in the exercise notice within two trading days following the date of exercise (subject to the ‘cashless
exercise’ arrangements described below).

Cashless Exercise. If, at the time a holder exercises its warrants, a registration statement registering the issuance of the securities underlying
the warrants under the Securities Act is not then effective or available and an exemption from registration under the Securities Act is
not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such
exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in
part) the net number of Depositary Shares determined according to a formula set forth in the warrants.

Exercise Price.The exercise price of each Series G Warrant, Series H Warrant and Warrant Agent Warrants is $62.50 per Depositary Share.

Beneficial Ownership Limitation. A holder shall have no right to exercise any portion of a warrant, to the extent that, after giving effect to
such exercise, such holder, together with such holder’s affiliates, and any persons acting as a group together with such holder
or any such affiliate, would beneficially own in excess of 9.99% or 4.99%, at the holders determination, of the number of Ordinary Shares
outstanding immediately after giving effect to the issuance of the Ordinary Shares